Core Viewpoint - Recently, Asia-Pacific Pharmaceutical (002370.SZ) received a notification from the National Medical Products Administration stating that the application for the consistency evaluation of Diltiazem Hydrochloride Tablets was not approved due to the inability of the bioequivalence study to support a bioequivalence conclusion [1] Group 1 - The application for the consistency evaluation was submitted in November 2024 and was accepted by the National Medical Products Administration [1] - The reason for the disapproval was that the bioequivalence study did not support the conclusion of bioequivalence [1] - The disapproval of Diltiazem Hydrochloride Tablets will not have a significant impact on the company's current performance [1] Group 2 - The company plans to improve the relevant experimental research of the drug and will reapply for approval in the future [1]

Core Viewpoint - Recently, Asia-Pacific Pharmaceutical (002370.SZ) received a notification from the National Medical Products Administration stating that the application for the consistency evaluation of Diltiazem Hydrochloride Tablets was not approved due to the inability of the bioequivalence study to support a bioequivalence conclusion [1] Group 1 - The application for the consistency evaluation of Diltiazem Hydrochloride Tablets was submitted in November 2024 and accepted by the National Medical Products Administration [1] - The reason for the disapproval was that the bioequivalence study conducted could not support the conclusion of bioequivalence [1] - The disapproval of Diltiazem Hydrochloride Tablets will not have a significant impact on the company's current performance, and the company plans to improve the relevant experimental research before resubmitting the application [1]

证券代码：002370 证券简称：亚太药业 公告编号：2025-091 浙江亚太药业股份有限公司 关于收到药品补充申请不予批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 浙江亚太药业股份有限公司（以下简称"公司"）于近日收到国 家药品监督管理局下发的关于盐酸地尔硫䓬片一致性评价的申请不 予批准的通知书。现将相关情况公告如下： 一、产品相关情况 三、对公司的影响及风险提示 本次盐酸地尔硫䓬片不予批准不会对公司当期业绩产生重大影 响，后续公司将完善该药品的相关试验研究工作后重新申报申请。药 品研发具有周期长、环节多的特点，容易受到一些不确定性因素的影 响，公司将严格按照相关法律法规及时履行信息披露义务，敬请广大 - 1 - 盐酸地尔硫䓬片适用于心绞痛和轻、中度高血压的治疗。 二、通知书主要内容 产品名称：盐酸地尔硫䓬片 受理号：CYHB2450*** 结论：根据《中华人民共和国药品管理法》的有关规定，经审查， 本品不符合仿制药质量和疗效一致性评价有关要求，不予批准。 公司于2024年11月向国家药品监督管理局递交该产品的一致性 评价申请并予以受理 ...

Group 1: Institutional Trading Insights - A total of 36 stocks were listed on the institutional trading leaderboard, with 19 stocks experiencing net buying and 17 stocks facing net selling [1] - The top three stocks with the highest net buying by institutions were: Haixia Innovation (224 million), Asia-Pacific Pharmaceutical (88.31 million), and Shenzhou Information (63.68 million) [1] Group 2: Company Profiles - Haixia Innovation, a local company in Fujian, specializes in intelligent solutions for building and public safety management, focusing on smart construction and public safety management [2] - The company is backed by four institutions with a net buying amount of 224 million [2] - Xiamen State-owned Assets Supervision and Administration Commission holds a controlling stake in Xiamen Construction Machinery, which primarily manufactures loaders, excavators, and shield machines [4] Group 3: Industry Developments - The 27th Harbin Ice and Snow World is currently under preparation, with the park area expanding to 1.2 million square meters and a total ice and snow usage of 400,000 cubic meters, marking a record high [5]

Group 1 - The core point of the article highlights that Asia-Pacific Pharmaceutical's stock rose by 3.90% with a turnover rate of 38.87% and a trading volume of 2.592 billion yuan, indicating strong market interest [2] - Institutional investors net bought 88.31 million yuan worth of shares, with a total buying amount of 346 million yuan and selling amount of 257 million yuan from the top five buying and selling seats [2] - The stock has appeared on the daily trading list 15 times in the past six months, with an average price increase of 2.36% the day after being listed and an average increase of 4.11% over the following five days [2] Group 2 - The main capital flow indicates a net outflow of 104 million yuan today, with large orders contributing to a net outflow of 16.04 million yuan and a net outflow of 87.87 million yuan from larger funds [2] - Over the past five days, the stock has seen a net inflow of 320 million yuan in principal funds, suggesting a positive trend in investor sentiment [2] - Detailed trading data shows that institutional special seats were active in both buying and selling, with significant amounts traded among the top five buying and selling seats [2]

Group 1 - The core point of the article highlights that Asia-Pacific Pharmaceutical achieved a record trading volume of 2.46 billion yuan, marking the highest since its listing [1] - The latest stock price increased by 3.33%, with a turnover rate of 36.91% [1] - The previous trading day's total transaction volume for the stock was 1.44 billion yuan [1] Group 2 - Asia-Pacific Pharmaceutical Co., Ltd. was established on December 31, 2001, with a registered capital of 745.67 million yuan [1]

Market Overview - On November 3, the total trading volume of the Shanghai and Shenzhen stock markets reached 2.11 trillion, a decrease of 210.7 billion compared to the previous trading day [1] - The sectors that performed well included thorium-based molten salt concepts, AI applications, coal, and Hainan Free Trade Zone, while small metals and battery sectors saw declines [1] High-Performance Stocks - *ST Dongyi achieved a 5.01% increase, marking its 15th consecutive trading day of gains [3] - *ST Wanfang also rose by 5.01%, with 13 consecutive days of gains [3] - ST Zhongdi increased by 4.97%, achieving 12 consecutive days of gains [3] - Pingtan Development surged by 10.03%, with 9 consecutive days of gains attributed to strong quarterly report growth [3] - An Tai Group rose by 9.97%, with 7 consecutive days of gains due to reduced losses and a focus on circular economy [3] Trading Dynamics - The top three net purchases on the daily leaderboard were Tai Chi Industrial, Aerospace Intelligent Equipment, and Shenzhou Information, with net purchases of 330 million, 328 million, and 326 million respectively [5] - The top three net sales were Kaimete Gas, Hongrun Construction, and Siwei Control, with net sales of 236 million, 140 million, and 134 million respectively [7] Sector Highlights - Aerospace Intelligent Equipment saw a significant increase of 19.98%, with a trading volume of 21.56 billion and a net institutional purchase of 69.42 million [19] - Shenzhou Information also increased by 10.03%, with a trading volume of 42.94 billion, although it faced a slight net institutional sell-off of 555,100 [19] - Kaimete Gas experienced a decline of 9.96%, with a trading volume of 30.27 billion and a net institutional sell-off of 1.08 billion [19] Company-Specific Insights - Tai Chi Industrial is focusing on semiconductor packaging and testing services, with a buyback plan approved for 100-120 million shares at a price not exceeding 10.38 yuan per share [10][14] - Aerospace Intelligent Equipment has been involved in the development of thorium-based molten salt reactors, which have shown promising results in recent tests [14] - Kaimete Gas reported a 13.72% decline in net profit for Q3 2025, reflecting challenges in the photolithography sector [17]

Core Insights - On November 3, the Shanghai Composite Index rose by 0.55%, with institutional investors appearing on the trading lists of 29 stocks, net buying 9 and net selling 20 [1][2]. Institutional Trading Summary - The stock with the highest net buying by institutional seats was Asia-Pacific Pharmaceutical, which closed at the daily limit with a turnover rate of 22.38% and a transaction amount of 1.442 billion yuan. The net buying amounted to 105.91 million yuan [2][5]. - Aerospace Intelligent Equipment also closed at the daily limit, with a turnover rate of 13.28% and a transaction amount of 2.156 billion yuan, resulting in a net buying of 69.42 million yuan [2][5]. - Aerospace Science and Technology closed at the daily limit with a turnover rate of 12.85% and a transaction amount of 2.048 billion yuan, leading to a net buying of 60.05 million yuan [2][6]. Market Performance - The average increase of stocks with institutional net buying was 5.77%, outperforming the Shanghai Composite Index. Notable performers included Aerospace Intelligent Equipment and China New Group, both closing at the daily limit [3]. - Historical data indicates that stocks with institutional net buying have a 49.79% probability of rising the next day and a 51.03% chance of outperforming the Shanghai Composite Index [3]. Earnings Forecasts - Among the stocks with institutional net buying, two provided earnings forecasts for 2025, with one expected to see a profit increase. The highest projected net profit growth was for Taikai Ying, estimated at 173 million yuan, representing a year-on-year increase of 10.44% [3]. Net Selling Summary - The stock with the highest net selling by institutional seats was Thinking Control, which saw a net selling of 125.29 million yuan due to a daily decline of 10.42% [3][6]. - Kaimete Gas also appeared on the trading list with a net selling of 107.61 million yuan, attributed to a daily decline of 10.40% [4][6]. Deep and Hong Kong Stock Connect - On November 3, 16 stocks on the trading list had appearances from Deep and Hong Kong Stock Connect, with net buying in stocks like Aerospace Intelligent Equipment and Aerospace Science and Technology, amounting to 93.44 million yuan and 89.74 million yuan respectively [7][8]. - Conversely, Kaimete Gas and Thinking Control were among those with significant net selling, with amounts of 145 million yuan and 34.63 million yuan respectively [7][8].

Core Viewpoint - On November 3, the Shanghai Composite Index rose by 0.55%, with institutional investors appearing on the trading lists of 29 stocks, net buying 9 and net selling 20 [1] Institutional Trading Summary - The stock with the highest net buying by institutional seats was Asia-Pacific Pharmaceutical, which closed at the daily limit with a turnover rate of 22.38% and a transaction amount of 1.442 billion [2] - Aerospace Intelligent Equipment also closed at the daily limit, with a turnover rate of 13.28% and a transaction amount of 2.156 billion, showing a net buying of 694.241 million from institutional seats [2] - Aerospace Technology closed at the daily limit as well, with a turnover rate of 12.85% and a transaction amount of 2.048 billion, with institutional net buying of 600.465 million [2] Market Performance - The average increase of stocks with institutional net buying was 5.77%, outperforming the Shanghai Composite Index [3] - Stocks like Aerospace Intelligent Equipment and China New Group showed strong performance, closing at the daily limit [3] - Historical data indicates that stocks with institutional net buying have a 49.79% probability of rising the next day and a 51.03% probability of outperforming the Shanghai Composite Index [3] Earnings Forecasts - Among the stocks with institutional net buying, two provided earnings forecasts for 2025, with one expected to see a profit increase [3] - The stock with the highest expected net profit growth is Taikai Ying, with a projected net profit of 173 million, representing a year-on-year increase of 10.44% [3] Net Selling Summary - The stock with the highest net selling by institutions was Thinking Control, which saw a net selling of 1.253 billion due to a daily decline of 10.42% [3] - Other notable net sellers included Kaimete Gas and Rongxin Culture, with net selling amounts of 1.076 billion and 623.089 million respectively [4][6] Deep and Shanghai Stock Connect - On November 3, 16 stocks on the trading list had appearances from Deep and Shanghai Stock Connect, with net buying in stocks like Aerospace Intelligent Equipment and Aerospace Technology [7] - The net buying amounts for these stocks were 934.410 million and 897.404 million respectively [7]

Summary of Key Points Core Viewpoint - On November 3, a total of 42 stocks were identified with institutional activity, with 13 stocks showing net buying and 29 stocks showing net selling by institutions [1]. Institutional Net Buying - The top three stocks with the highest net buying by institutions were: - Asia-Pacific Pharmaceutical: Net buying amount of 106 million yuan, with a daily increase of 9.96% [2] - Dingsheng New Materials: Net buying amount of 82.79 million yuan, with a daily increase of 6.64% [2] - Aerospace Intelligent Equipment: Net buying amount of 69.42 million yuan, with a daily increase of 19.98% [2] Institutional Net Selling - The top three stocks with the highest net selling by institutions were: - Sanofi China: Net outflow amount of 211 million yuan, with a daily increase of 7.88% [4] - Thinking Control: Net outflow amount of 125.29 million yuan, with a daily decrease of 9.87% [4] - Kaimete Gas: Net outflow amount of 107.61 million yuan, with a daily decrease of 9.96% [4]